Elyssa Benedikt Email & Phone Number

- Commercial lead on partnered hemophilia drug with plans to enter Phase 3 early 2017- Collaborated closely with partner in defining early brand strategy and commercial requirements, refining TPP, engaging with medical education, patient advocacy, KOL management- Reviewed 2016 investment plan and budgets; led business planning process for 2017 with.

- Commercial lead on four ophthalmology programs, including three gene therapies for rare ocular diseases (Phase I/II)- Prepared forecast, supported valuation and and due diligence on $300M acquisition of CAPRELSA- Prepared commercial assessments for internal pipeline programs to support investment decisions- Conducted KOL interviews, prepared forecast and.

- Prepared assessments of new opportunities for leadership approval. Resulted in offering 6 non-binding offers - Coordinated due diligence (R&D, clinical, IP, manufacturing, etc.) for several opportunities

- Developed 2014 brand plan and managed about $1.0 million budget for Genzyme’s unbranded educational website for HCPs and consumers, including content development, KOL engagement, and promotion - Coordinated promotional campaign via PeerDirect, including email and direct mail promotion - Helped train about one hundred new Aubagio speakers, coordinating.

OverviewThe Biomedical Enterprise Program (BEP) is jointly administered by the Harvard-MIT Division of Health Sciences and Technology (HST) and the MIT Sloan School of Management. The program exposes students to an integrated curriculum focused on the complex process of product development and commercialization in the health care industry. BEP rigorously.

- Analyzed analog development programs to recommend strategy for critical project; analysiswas referenced in strategy meetings and distributed to senior management including CEO

Consulting firm that developed P&R and marketing strategies for 24/25 top pharma- Managed day-to-day activities for diverse global teams on projects spanning the US, Europe, Asia and Latin America for major firms (including Novartis, J&J, Pfizer, Bayer, and AstraZeneca)- Developed marketing and pricing strategy for >15 products- Researched treatment.

Mental Health Policy